The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs
Open accessAbstract
// Rafael Barreto 1 , David L. Waning 2, 3, 5 , Hongyu Gao 4 , Yunlong Liu 4 , Teresa A. Zimmers 1, 2, 5 , Andrea Bonetto 1, 2, 5 1 Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA 2 Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA 3 Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA 4 Department of Medical and Molecular Genetics, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA 5 IUPUI Center for Cachexia Research, Innovation and Therapy, Indianapolis, IN 46202, USA Correspondence to: Andrea Bonetto, email: abonetto@iu.edu Keywords: chemotherapy, cachexia, muscle wasting, MAPKs, mitochondria Received: April 11, 2016 Accepted: May 16, 2016 Published: June 02, 2016 ABSTRACT Cachexia affects the majority of cancer patients, with currently no effective treatments. Cachexia is defined by increased fatigue and loss of muscle function resulting from muscle and fat depletion. Previous studies suggest that chemotherapy may contribute to cachexia, although the causes responsible for this association are not clear. The purpose of this study was to investigate the mechanism(s) associated with chemotherapy-related effects on body composition and muscle function. Normal mice were administered chemotherapy regimens used for the treatment of colorectal cancer, such as Folfox (5-FU, leucovorin, oxaliplatin) or Folfiri (5-FU, leucovorin, irinotecan) for 5 weeks. The animals that received chemotherapy exhibited concurrent loss of muscle mass and muscle weakness. Consistently with previous findings, muscle wasting was associated with up-regulation of ERK1/2 and p38 MAPKs. No changes in ubiquitin-dependent proteolysis or in the expression of TGFβ-family members were detected. Further, marked decreases in mitochondrial content, associated with abnormalities at the sarcomeric level and with increase in the number of glycolytic fibers were observed in the muscle of mice receiving chemotherapy. Finally, ACVR2B/Fc or PD98059 prevented Folfiri-associated ERK1/2 activation and myofiber atrophy in C2C12 cultures. Our findings demonstrate that chemotherapy promotes MAPK-dependent muscle atrophy as well as mitochondrial depletion and alterations of the sarcomeric units. Therefore, these findings suggest that chemotherapy potentially plays a causative role in the occurrence of muscle loss and weakness. Moreover, the present observations provide a strong rationale for testing ACVR2B/Fc or MEK1 inhibitors in combination with anticancer drugs as novel strategies aimed at preventing chemotherapy-associated muscle atrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539 · cited 1×
“Interestingly, the skeletal muscle proteolytic systems, commonly implicated in conditions characterized by muscle atrophy [44], did not seem to be responsible for the muscle wasting caused by chemotherapy in this and our models, as also supported by the absence of modulation of proteasome activity and ubiquitin ligase…”
BackgroundTabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Milan, G., Romanello, V., Pescatore, F., Armani, A., Paik, J.-H., Frasson, L., Seydel, A., Zhao, J., Abraham, R., Goldberg, A. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7670 · Cited by 709
Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy
Lai, K.-M. V., Gonzalez, M., Poueymirou, W. T., Kline, W. O., Na, E., Zlotchenko, E., Stitt, T. N., Economides, A. N., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9295-9304.2004 · Cited by 442
Bonetto, A., Aydogdu, T., Kunzevitzky, N., Guttridge, D. C., Khuri, S., Koniaris, L. G., & Zimmers, T. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022538 · Cited by 348 · cited 1×
“Therefore, this evidence is consistent with our previous findings reported in the muscle of C26bearing animals, suggesting that skeletal muscle protein breakdown may contribute to the activation of a systemic acute phase response and to the sustainment of an overall inflammatory state [58].”
ResultSelf-citationSilva, K. A. S., Dong, J., Dong, Y., Dong, Y., Schor, N., Tweardy, D. J., Zhang, L., & Mitch, W. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641514 · Cited by 229
Ozola Zalite, I., Zykus, R., Francisco Gonzalez, M., Saygili, F., Pukitis, A., Gaujoux, S., Charnley, R. M., & Lyadov, V. (2015) · Pancreatology · doi:10.1016/j.pan.2014.11.006 · Cited by 174
Wright, L. E., Brandon, A. E., Hoy, A. J., Forsberg, G.-B., Lelliott, C. J., Reznick, J., Löfgren, L., Oscarsson, J., Strömstedt, M., Cooney, G. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2068-x · Cited by 57
Cited by
Clifford, B. K., Mizrahi, D., Sandler, C. X., Barry, B. K., Simar, D., Wakefield, C. E., & Goldstein, D. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-017-3964-5 · Cited by 278
Cachexia: A systemic consequence of progressive, unresolved disease
Ferrer, M., Anthony, T. G., Ayres, J. S., Biffi, G., Brown, J. C., Caan, B. J., Cespedes Feliciano, E. M., Coll, A. P., Dunne, R. F., Goncalves, M. D., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.028 · Cited by 260
Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways
Barreto, R., Mandili, G., Witzmann, F. A., Novelli, F., Zimmers, T. A., & Bonetto, A. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00472 · Cited by 183
Self-citationMyostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Wang, D., Sun, H., Song, G., Yang, Y., Zou, X., Han, P., & Li, S. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700941 · Cited by 102
Mitochondrial dynamics in cancer-induced cachexia
van der Ende, M., Grefte, S., Plas, R., Meijerink, J., Witkamp, R. F., Keijer, J., & van Norren, K. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.008 · Cited by 87
PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia
Pin, F., Novinger, L. J., Huot, J. R., Harris, R. A., Couch, M. E., O'Connell, T. M., & Bonetto, A. (2019) · The FASEB Journal · doi:10.1096/fj.201802799r · Cited by 81
Self-citation
Metadata
- Authors
- Barreto, R., Waning, D. L., Gao, H., Liu, Y., Zimmers, T. A., & Bonetto, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-02
- Volume
- 7
- Issue
- 28
- Pages
- 43442-43460
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2413238603
- Cited by
- 196
- References
- 10
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.